Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: A multicentre, open-label, randomised controlled trial
Lancet Rheumatol 224;6(3):e168–77 DOI 10.1016/S2665-9913(23)00320-X
Mycophenolate mofetil (MMF) withdrawal was not significantly inferior to MMF maintenance through Week 60 in patients with SLE that had been treated with MMF for ≥1 year.
Patients with SLE (N=100) were randomised 1:1 to MMF maintenance or MMF withdrawal for a period of 60 weeks. The aim of the study was to assess the effects of MMF withdrawal on the risk of disease activation in patients with quiescent SLE with long-term MMD therapy, and the probability of clinically significant disease reactivation by Week 60 was the primary endpoint.
Keywords:
